EMEkaterina V. Motyko

Ekaterina V. Motyko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ekaterina V. Motyko has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular genetic characteristics and pathogenetic mechanisms of mantle cell lymphoma: a cohort study

    by Nadezhda N. Nemstsveridze, Ekaterina V. Motyko, Anna N. Kirienko, Daria V. Kustova, Irina S. Martynkevich

    BACKGROUND: In addition to the characteristic t(11;14) translocation, the genome of mantle cell lymphoma is distinguished by numerous secondary chromosomal aberrations and molecular genetic alterations. AIM: This study aimed to assess the mutational profile of mantle cell lymphoma, identify the most frequent genetic aberrations, and determine their impact on overall survival. METHODS: Twenty-four patients with classical stage III–IV mantle cell lymphoma were included. All patients underwent conventional cytogenetic analysis, fluorescence in situ hybridization, and next-generation sequencing. Karyotypes were interpreted in accordance with the International System for Human Cytogenomic Nomenclature (ISCN). Moreover, survival functions were estimated using the Kaplan–Meier method with the log-rank test. The relationship between survival time and independent variables was evaluated using univariate and multivariate Cox regression analyses. RESULTS: Conventional cytogenetic analysis determined a normal karyotype in 19 (79.2%) patients. The t(11;14) translocation was detected in three patients, 17p deletion in two (8%), and a complex karyotype in two (8%). Fluorescence in situ hybridization analysis identified t(11;14) translocation in 16 (67%) patients, TP53/17p13 deletion in 4 (17%), and MYC/8q24 rearrangement in 3 (12.5%). TP53/17p13 deletion induced an independent negative effect on overall survival (p = 0.020). NGS revealed the most frequent mutations in ATM (36%), RYR1 (27%), BCR (27%), and KMT2D (23%) genes. Significant associations were observed between FAT1 and BCR (p = 0.013), MGA and KMT2D (p = 0.024), and DNMT3A and KMT2D (p = 0.043) mutations. Among the detected variants, the ATM mutation predicted poor overall survival; however, its statistical significance was lost after adjusting for TP53/17p13 deletion (p = 0.099). CONCLUSION: Analysis of the mutational profile revealed the most frequent aberrations—mutations in ATM, BCR, and KMT2D genes—in mantle cell lymphoma, which potentially contribute to the tumor’s pathogenesis.

  • Open Access

    DNA Methylation Genes in Multiple Myeloma: What We Already Know and How It Can Be Used?

    by Daria Aleksandrovna Chebykina, E. V. Motyko, A. N. Kirienko, D. V. Kustova, O. B. Krysiuk, S. V. Sidorkevich, I. S. Martynkevich

    BACKGROUND. The last 20 years have seen a substantial evolution of diagnostic methods and innovation approaches to analyzing genome and transcriptome of tumor cells. Underresearched, however, is the value of aberrant patterns of DNA methylation or methylation-modifying genes in the pathogenesis of multiple myeloma (MM) development and in the mechanisms of tumor progression. Mutation detection by next-generation sequencing (NGS) in disease relapse- and/or drug resistance-associated genes provides the basis for identifying novel targets for drug therapy. AIM. To analyze the molecular genetic landscape and prognostic value of NGS detected mutations in the genes of MM patients. MATERIALS & METHODS. This prospective study enrolls 45 MM patients treated at the Russian Research Institute of Hematology and Transfusiology (Saint Petersburg) from 2011 to the present. The median age of patients was 60 years (range 38–81 years). All patients received mutation screening using a NGS panel with 118 genes. The cells of bone marrow aspirate were subjected to the analysis. A comprehensive study of genetic status included also the standard karyotyping and FISH analysis. RESULTS. Somatic mutations in DNA methylation regulatory genes DNMT3A and TET2 had no significant impact either on objective response or long-term survival rates. However, in case of somatic mutations detected in gene NOTCH1 or ATM, the 3-year progression-free survival was 27.3 % (95% confidence interval [95% CI] 8.0–83.5 %) vs. 59.0 % (95% CI 42.3–82.9 %) without these mutations, the 3-year overall survival was 64 % (95% CI 42.7–96.4 %) and 95% (95% CI 87–100 %), respectively. CONCLUSION. Mutation status of DNA methylation genes has no significant impact either on antitumor response or on long-term survival rates in MM patients. However, genuine potential of of DNA methylation patterns and DNA methylation-modifying genes has not yet been evaluated. Further studies need to be conducted in this field to stratify the risks and to improve the treatment strategy. DNA methylation-modulating agents may eventually join the arsenal of therapeutic options for MM.

  • Open Access

    NGS analysis of the mutational profile of patients with Ph-negative myeloproliferative neoplasms

    by A. N. Kirienko, E. V. Motyko, E. V. Efremova, D. V. Kustova, T. N. Gert, I. V. Leppyanen, V. A. Shuvaev, I. S. Martynkevich

    Introduction. The identification of driver mutations in the JAK2, CALR, and MPL genes is a gold standard approach in the molecular diagnosis of patients with Ph-negative myeloproliferative neoplasms (Ph-MPNs). However, such patients are characterized by a heterogenous genomic landscape. Standard molecular genetic methods cannot be used to identify most somatic mutations, thus failing to provide a comprehensive understanding of the course and prognosis of Ph-MPNs and to confirm the clonality of the disease in patients with triple-negative status. The next generation sequencing (NGS) technology allows simultaneous analysis of an extensive panel of genes and identification of both pathogenic and driver mutations.Aim. To evaluate the possibility of using NGS to study the mutational status of patients with Ph-negative MPNs and to analyze the effect of identified pathogenic mutations on patient survival.Materials and methods. The study included 83 patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis aged from 19 to 85 years (the median onset age of 51 years). For all patients, sequencing was performed using a myeloid panel of 118 genes with an average reading depth of 1000x on MiSeq (Illumina, USA). The clinical significance of the mutations was determined using the COSMIC and Franklin databases. The survival rate was analyzed using the Kaplan–Meyer method followed by assessment of statistical significance using the Cox-Mantel test in the GraphPad Prism 8 environment.Results. Pathogenic mutations in 23 genes were detected in 39 (46%) patients out of the total cohort of patients. The most frequent mutations were detected in the ASXL1 gene in 25% of patients, which reduced event-free survival by 50.3% (Me = 7.83 years vs 15.75 years). The pathogenic mutations identified in other genes combined with mutations in driver genes also decreased event-free survival compared to patients with isolated driver mutations. Two or more pathogenic mutations significantly reduced event-free survival compared to patients with only one pathogenic mutation. The NGS method was also capable of identifying pathogenic mutations in 8 out of 10 triple-negative patients studied, thus confirming the clonality of the disease.Conclusions. The next-generation sequencing (NGS) method using a panel of 118 genes is an effective tool in identifying predictively significant mutations important for selecting the most effective personalized therapy to achieve hematologic response.

  • Open Access

    Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia

    by D. V. Kustova, E. V. Motyko, A. N. Kirienko, T. N. Gert, I. V. Leppyanen, M. P. Bakay, E. V. Efremova, E. V. Morozova, E. G. Lomaia, V. A. Shuvaev, et al.

    Background. Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors achieve durable optimal responses. Loss of the achieved molecular response is observed in 15–30 % of patients. Mutations in the BCR::ABL kinase domain are one of the most common mechanisms for the development of resistance to tyrosine kinase inhibitors.Aim. To conduct a retrospective analysis of the BCR::ABL kinase domain mutational profile in patients with CML observed at the Russian Research Institute of Hematology and Transfusiology from 2012 to 2023. To assess the impact of mutations type and number on the rate of achieving a major molecular response (MMR). To study the risk of MMR loss depending on the therapy line and existing mutational status.Materials and methods. 1831 patients with CML were examined at different times. The mutational status of the BCR::ABL kinase domain was analyzed by direct Sanger sequencing. A standard cytogenetic study was carried out using GTG banding technology with the analysis of at least 20 metaphase plates.Results. Mutations in the BCR::ABL kinase domain were identified in 27.6 % of the total studied patients. The most common mutation, 6.3 % in the overall group or 22.7 % among patients with mutations, was the T315I mutation. Additional chromosomal aberrations (ACAs) were detected in Ph-positive cells in 20.5 % of patients, in Ph-negative clones in 3.9 % of cases (p = 0.0001). The frequency of ACAs detection did not statistically significantly differ (p = 0.25) between patients with BCR::ABL mutations (23.5 %) and with a negative mutation status (17.7 %), and the presence of mutations in the kinase domain did not correlate with ACAs in Ph-positive clones (p = 0.73). However, the frequency of T315I mutation detection in Ph-positive cells had significant differences: 40.9 % in combination with ACAs and 21 % without ACAs (p = 0.032). Patients with the T315I mutation had significantly worse MMR than patients with mutations in other BCR::ABL regions (p = 0.04) and patients without mutations (p = 0.02). The probability of MMR achieving did not differ significantly between patients with different numbers of BCR::ABL mutations (p = 0.14). Loss of MMR occurred more often in patients with mutations (p = 0.04) and not depend on the line of therapy (p = 0.03).Conclusion. For complete monitoring and optimal choice of therapy, CML patients require not only monitoring of BCR::ABL relative expression level, but also standard cytogenetic and analysis of the mutational status.


  • Open Access

    Perspectives for next generation sequencing in patients with follicular lymphoma

    by E. O. Kunevich, I. S. Martynkevich, M. A. Mikhaleva, А. N. Bogdanov, E. V. Motyko, A. Yu. Kuvshinov, S. V. Sidorkevich, S. V. Voloshin

    Aim. To study the prognostic significance of gene mutations and intracellular signaling pathways involved in lymphomagenesis in patients with follicular lymphoma using next generation sequencing (NGS).Materials and methods. The prospective study included 26 patients with a median age of 51.5 years. Mutational screening was performed for cohort using custom NGS Panel of 118 genes. Gene set enrichment analysis (GSEA) was performed using Metascape. The data was analyzed in SPSS Statistics 26 and R 4.2.2.Results. The highest mutation frequency was noted in the genes: KMT2C – 50 %, KMT2D – 50 %, CREBBP – 31 %, NOTCH2 – 31 %, GNAS – 23 %. Missense mutations occurred with a frequency of 84.3 %. ARID1A gene mutation is an unfavorable prognostic factor according to progressive-free (p = 0.014) and event-free (p = 0.029) survival analysis. Tumor mutation burden (TMB) was defined as the number of mutations per megabase (Mb) of the coding sequence, the median TMB was 5.0 (3.3–8.3) mutations/Mb. The TMB threshold of 6 mutations/Mb divided patients into groups with high (44 %) and low (56 %) TMB. In the high TMB group, 2-year event-free survival was 27.3 % (95 % confidence interval 6.0–61.0), which was significantly lower than in low TMB group – 72.7 % (95 % confidence interval 41.9–91.6; p = 0.037). The most enriched cellular pathways according to GSEA results were regulation of cell activation (–log10(q-value) = 6.357), chromatin remodeling (–log10(q-value) = 5.707), histone modification (–log10(q-value) = 4.569). We have also demonstrated other possibilities of GSEA using follicular lymphoma as an example.Conclusion. TMB is a significant prognostic factor in patients with follicular lymphoma. We have shown that mutations in the MYC, CREBBP, EZH2, KMT2D genes lead to dysregulation in several intracellular processes, mediating complex molecular changes. The most enriched intracellular pathways in follicular lymphoma are those of chromatin remodeling, regulation of cell activation and histone modification.